View all cases
UPC CFI 697/2025
Jul 31, 2025·EP2377536 · Methods of Using Sustained Release Aminopyridine Compositions
- Case details
- StatusCase ClosedSet aside on appeal, Apr 27, 2026ActionProvisional measuresCategoryProvisional measures
- Parties
- Claimants
- Merz Pharmaceuticals LLCOperating co.
- Merz Therapeutics GmbHOperating co.
- Merz Pharma FranceOperating co.
Representatives- Laëtitia Bénard-A&O Shearman
- Charles Tuffreau-A&O Shearman
- Edward Oates
- Agathe Michel-De Cazotte-Carpmaels & Ransford
Respondents- Viatris SantéOperating co.
Representatives- Marc Lauzeral-Schertenleib
- Denis Schertenleib-Schertenleib
- Division
- Paris LD
- Technology
- ChemistryPharmaceuticals
- Language
- English
- First decided
- Nov 21, 2025
- EPO Opposition
- Actavis Group PTC ehfAdmissible2013-12-05
- Synthon B.V.Admissible2013-12-06
- neuraxpharm Arzneimittel GmbHAdmissible2013-12-06
- Appealed
- Set aside by UPC CoA 917/2025 · Apr 27, 2026
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
| Preliminary injunction granted | Median days to first decision | |
|---|---|---|
| All UPC | 54% (38/70) | 124 |
| Paris LD | Locked | Locked |
| Judge Camille Lignières | Locked | Locked |
| Judge Carine Gillet | Locked | Locked |
| Judge Samuel Granata | Locked | Locked |
| Judge Rainer Friedrich | Locked | Locked |
At the UPC: Merz Pharmaceuticals LLC (7 cases)·Viatris Santé (6 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 5 other proceedings
UPC CFI 3259/2026·UPC CFI 1901/2026·UPC CoA 917/2025·UPC CoA 906/2025·UPC APP 36985/2025
1 other defendants litigating the same or a related patent
Decisions
- 2025-11-21Application for provisional measuresPublic
Summary: The Paris Local Division (full panel) rejected Merz's application for provisional measures against Viatris concerning French SPC 033 (based on EP 2 377 536) and the generic product 'FAMPRIDINE VIATRIS LP 10 mg', holding that Merz failed to seek provisional measures within the reasonable time required by R.211.4 RoP: Merz was, or should have been, aware of the imminent infringement well before it filed on 31 July 2025 (at the latest from 2 January 2025, when it recovered direct exploitation rights to FAMPYRA, itself five months before it sent a warning letter, and six months before it applied to the Court after Viatris confirmed the French launch). The Court did not reach the merits of infringement or SPC validity, and ordered Merz to pay Viatris EUR 56,000 in interim costs.
Show the legal issues (4)
- Unreasonable delay in seeking provisional measures (R.211.4 RoP)
- Starting point for calculating diligence when the alleged infringer is a generic manufacturer (imminent infringement under Art. 62.1 UPCA / R.211.2 RoP vs. actual market launch)
- Whether a Court of Appeal decision interpreting R.211.4 RoP (Boehringer v Zentiva, 13 Aug 2025) creates a new legal situation that cannot be invoked against a party for legal-certainty reasons
- Interim award of costs on rejection of a provisional-measures application (R.211.1(d) RoP)
Documents
| Document title | Date | Public |
|---|---|---|
| Case closed | 2026-06-08 | Not public |
| Communication | 2025-11-28 | Not public |
| Cover sheet | 2025-11-28 | Not public |
| Application document Claimant | 2025-11-28 | Not public |
| Receipt | 2025-11-28 | Not public |
| Communication | 2025-11-21 | Not public |
| Order | 2025-11-21 | Public |
| Decision | 2025-11-21 | Not public |
| Final Order | 2025-11-21 | Not public |
| Oral procedure closed | 2025-11-21 | Not public |
| Written procedure closed | 2025-11-21 | Not public |
| Order | 2025-10-29 | Not public |
| Order | 2025-10-29 | Public |
| Cover sheet | 2025-10-14 | Not public |
| Fee | 2025-10-14 | Not public |
| Application | 2025-10-14 | Not public |
| Proof of payment | 2025-10-14 | Not public |
| Receipt | 2025-10-14 | Not public |
| Communication | 2025-10-10 | Not public |
| Cover sheet | 2025-10-09 | Not public |
| Fee | 2025-10-09 | Not public |
| Application | 2025-10-09 | Not public |
| Other document | 2025-10-09 | Not public |
| Proof of payment | 2025-10-09 | Not public |
| Receipt | 2025-10-09 | Not public |
| Order | 2025-10-07 | Not public |
| Order | 2025-10-07 | Not public |
| Order | 2025-10-07 | Not public |
| Order | 2025-10-07 | Not public |
| Communication | 2025-10-06 | Not public |
| Communication | 2025-10-06 | Not public |
| Cover sheet | 2025-10-05 | Not public |
| Application | 2025-10-05 | Not public |
| Receipt | 2025-10-05 | Not public |
| Order | 2025-10-02 | Not public |
| Order | 2025-10-02 | Not public |
| Cover sheet | 2025-10-02 | Not public |
| Application | 2025-10-02 | Not public |
| Receipt | 2025-10-02 | Not public |
| Order | 2025-10-02 | Not public |
| Order | 2025-10-02 | Not public |
| Cover sheet | 2025-10-02 | Not public |
| Application | 2025-10-02 | Not public |
| Receipt | 2025-10-02 | Not public |
| Cover sheet | 2025-10-01 | Not public |
| Application | 2025-10-01 | Not public |
| Receipt | 2025-10-01 | Not public |
| Cover sheet | 2025-10-01 | Not public |
| Statement of reply | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Exhibit | 2025-10-01 | Not public |
| Receipt | 2025-10-01 | Not public |
| Communication | 2025-09-26 | Not public |
| Cover sheet | 2025-09-25 | Not public |
| Exhibit | 2025-09-25 | Not public |
| Exhibit | 2025-09-25 | Not public |
| Exhibit | 2025-09-25 | Not public |
| Exhibit | 2025-09-25 | Not public |
| Exhibit | 2025-09-25 | Not public |
| Other document | 2025-09-25 | Not public |
| Receipt | 2025-09-25 | Not public |
| Cover sheet | 2025-09-25 | Not public |
| Exhibit | 2025-09-25 | Not public |
| Other document | 2025-09-25 | Not public |
| Receipt | 2025-09-25 | Not public |
| Communication | 2025-09-25 | Not public |
| Order | 2025-09-24 | Not public |
| Order | 2025-09-24 | Not public |
| Receipt | 2025-09-18 | Not public |
| PC154 IQVIA Agreement GB | 2025-09-18 | Not public |
| PC149 IQVIA Data unredacted version GB | 2025-09-18 | Not public |
| 20250915 - Request v.def PDF-A signed | 2025-09-18 | Not public |
| PC149 IQVIA Data unredacted version GB | 2025-09-18 | Not public |
| Headnote-and-Keywords | 2025-09-17 | Not public |
| Outcome of the Order | 2025-09-17 | Not public |
| procedural order | 2025-09-17 | Public |
| Receipt | 2025-09-17 | Not public |
| Objection | 2025-09-16 | Not public |
| Receipt | 2025-09-16 | Not public |
| Receipt | 2025-09-16 | Not public |
| Request for procedural order | 2025-09-16 | Not public |
| PJ032 Decision de la Chambre de recours de lOEB 29 mai 2001 T 009198 GB | 2025-09-15 | Not public |
| PC050 Extract from the National Institutes of Health website FDA Drug Review and Approval GB | 2025-09-15 | Not public |
| PC083 Barus et al 2022 FR | 2025-09-15 | Not public |
| PJ078 Case law of the boards of Appeal ID108 GB | 2025-09-15 | Not public |
| PC081 ICHT topic 9 guideline on statistical principles for clinical trials September 1998 GB | 2025-09-15 | Not public |
| PC071 Germany ratiopharm 20240304 Revocation of patent EP 536 DE | 2025-09-15 | Not public |
| PJ058 TJ Paris Refere 17 juin 2021 RG 2153849 Cabazitaxel Sanofi c Ever Pharma FR | 2025-09-15 | Not public |
| PC084 AFSEP press release of 28 May 2025 FR | 2025-09-15 | Not public |
| PC137 They are looking for a superpill for Alzheimers Technologies News Standard 2013 BG | 2025-09-15 | Not public |
| PJ086 Court of Appeal 10x Genomics Harvard v NanoString UPC CoA 3352023 GB | 2025-09-15 | Not public |
| PC098 Le Progres Article Patients deprived of a medication due to a change of packaging 26 June 2025 FR | 2025-09-15 | Not public |
| PC097 Screenshots of patients testimonies online 1 2 FR | 2025-09-15 | Not public |
| PC102 Clinical studies in 20 questions Atelier Presse Clinical trials LEEM 19 May 2011 FR | 2025-09-15 | Not public |
| PJ067 LD Munich 15 November 2024 UPC CFI 152023 GB | 2025-09-15 | Not public |
| PJ082 Phosphodiesterase NL Appeal court of the Hague Appel 27082019 NL | 2025-09-15 | Not public |
| PC046 US 8 354 437 GB | 2025-09-15 | Not public |
| PJ024 JUB Cour dAppel 26 fevrier 2024 NanoString c 10x Genomics UPCCoA3352023 GB | 2025-09-15 | Not public |
| PC058 Federal Court of Appeal of Canada 8 August 2022 Acorda Therapeutics v Pharmascience Taro Pharmaceuticals A 145 20 | 2025-09-15 | Not public |
| PC074 USA 20170425 Delaware District Court 25 avril 2017 Acorda v Teva Roxane Mylan 14 882 GB | 2025-09-15 | Not public |
| PJ008 TJ Paris 29 septembre 2021 RG 21 55930 FR | 2025-09-15 | Not public |
| PC142 Kostadinova and Danchev 2019 GB | 2025-09-15 | Not public |
| PC129 Iqvia About us GB | 2025-09-15 | Not public |
| PC115 Sheeber et al 1996 Data analytic techniques for treatment outcome studies with pretest posttest measurements an ex | 2025-09-15 | Not public |
| PC061 L echelle EDSS Expanded Disability Status Scale FR | 2025-09-15 | Not public |
| PC005 EP 2 377 536 B2 GB | 2025-09-15 | Not public |
| PJ054 Cour dappel de Paris 14 fevrier 1991 Newtec International c Sfeima PIBD n504 IIII432 FR | 2025-09-15 | Not public |
| PJ055 TGI Paris 22 septembre 2017 1407707 FR | 2025-09-15 | Not public |
| PC024 Bever et al 1994 Juin Neurology 44 1054 1059 GB | 2025-09-15 | Not public |
| PJ049 Decision de la Chambre de recours 3502 de lOEB 29 octobre 2019 T 33515 FR | 2025-09-15 | Not public |
| PC062 Cohen Postgraduate Medicine Septembre 1999 GB | 2025-09-15 | Not public |
| PC031 SEC Overview GB | 2025-09-15 | Not public |
| PC014 Journal de la societe statistique de Paris 1956 FR | 2025-09-15 | Not public |
| PJ072 Hamburg Local Division 3 June 2024 UPCCFI1512024 GB | 2025-09-15 | Not public |
| PC011 Edwards and Aronson The Lancet Vol 356 October 7 2000 GB | 2025-09-15 | Not public |
| PC101 Report by Dr Christian Wolf dated 2 September 2022 GB | 2025-09-15 | Not public |
| PC067 EMEA Points to consider on the choice of non interiority margin 2004 GB | 2025-09-15 | Not public |
| PC016 Piece composite Synthese Wikipiedia sur l ecart type et la valeur P FR | 2025-09-15 | Not public |
| PJ083 Fingolimod DE OLG Dusseldorf Appel 03082023 DE | 2025-09-15 | Not public |
| PC048 US 8 663 685 GB | 2025-09-15 | Not public |
| PC140 OLG Munchen Acorda Therapeutics v Ratiopharm 6 October 2022 6 U 3044 22 DE | 2025-09-15 | Not public |
| PC089 RNB EP 536 FR | 2025-09-15 | Not public |
| PC128 Adverse exhibit No 503 Toumi et al External Reference Pricing Simulation GB | 2025-09-15 | Not public |
| PC051 Kaufman al 2000 The significant change for the Timed 25 Foot Walk in the Multiple Sclerosis Functional Composite M | 2025-09-15 | Not public |
| PJ076 UPC Court of Appeal 25 September 2024 UPCCoA1822024 GB | 2025-09-15 | Not public |
| Objection Viatris Sante 15092025 APP 339802025 compressed signed | 2025-09-15 | Not public |
| PJ068 Court of Appeal Biolitec v Light Guide Optics SIA Lightguide 24 February 2025 UPCCoA5402024 GB | 2025-09-15 | Not public |
| PJ036 TJ Paris 7 juin 2021 RG 2153474 Sanofi c Accord cabazitaxel FR | 2025-09-15 | Not public |
| PC066 EMEA 27 July 2000 Points to consider on switching betweend superiority and non inferiority GB | 2025-09-15 | Not public |
| PC028 van Diemen et al 1992 August GB | 2025-09-15 | Not public |
| PJ062 Directive 200448CE GB | 2025-09-15 | Not public |
| PC078 Info Sheet FAMPYRA 10mg sustained release tablet FR | 2025-09-15 | Not public |
| PC020 Merz acquires Fampyra GB | 2025-09-15 | Not public |
| PJ034 Cour dappel de Paris 18 Decembre 2018 RG n 1710112 FR | 2025-09-15 | Not public |
| PC122 Application for provisional measures GB | 2025-09-15 | Not public |
| PC086 Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects GB | 2025-09-15 | Not public |
| PC056 Polman Arch Neur Vol 51 novembre 1994 GB | 2025-09-15 | Not public |
| PC148 The fixing of the price and reimboursement rate sante gouv FR | 2025-09-15 | Not public |
| PJ043 BASF C25899 GB | 2025-09-15 | Not public |
| PC113 Vickers 2003 Hor many repeated measures in repeates measures designs Statistical issues for comparative Trials BMC | 2025-09-15 | Not public |
| PC055 Sheiner Clin Pharmacol Ther Volume 46 Number 1 Juillet 1989 GB | 2025-09-15 | Not public |
| PC133 SmPC Pymadin BG | 2025-09-15 | Not public |
| PC105 DTX 584 GB | 2025-09-15 | Not public |
| PC052 Schwid et al 2002 April GB | 2025-09-15 | Not public |
| PC130 4 aminopiridin Spinal Cord Injury Forum RU compressed | 2025-09-15 | Not public |
| PJ084 DMF BE Cour dAppel de Bruxelles Appel 30012023 NL | 2025-09-15 | Not public |
| PC013 Ting N Introduction and New Drug Development Process In Ting N editor Dose Finding in Drug Development Springer Ne | 2025-09-15 | Not public |
| PJ080 Munich Local Division 21 May 2024 UPCCFI432023 DE | 2025-09-15 | Not public |
| PC090 RNB CCP 033 FR | 2025-09-15 | Not public |
| PC138 Website of the faculty of medicine in Sofia BG | 2025-09-15 | Not public |
| PJ035 CA Paris 29 octobre 2019 ETYPHARM c MERCK RG n1803876 FR | 2025-09-15 | Not public |
| PC082 Extrait de la Base de Donnees Publique des Medicaments Fampridine Viatris 10 mg FR | 2025-09-15 | Not public |
| PJ012 Munich Local Division 27 August 2024 UPCCFI2012024 GB | 2025-09-15 | Not public |
| PC138 Website of the faculty of medicine in Sofia BG | 2025-09-15 | Not public |
| PC136 Russian State Archive of Scientific and Technical Documentation RU | 2025-09-15 | Not public |
| PC139 UPSTO Trademark Status Document Retrieval Pymadin Sopharma GB | 2025-09-15 | Not public |
| PC080 website of the Foundation for Research into Multiple Sclerosis FR | 2025-09-15 | Not public |
| PJ048 Decision de la Chambre de recours de lOEB 10 novembre 1988 T038187 GB | 2025-09-15 | Not public |
| PJ070 Dusseldorf Local Division 9 April 2024 UPCCFI4522023 DE | 2025-09-15 | Not public |
| PC075 Federal Court of Canada 15 May 2020 Acorda v Pharmascience and Taro T 1416 18 and T 220 19 GB | 2025-09-15 | Not public |
| PC079 Notice on the prices of Fampridine pharmaceutical specialities FR | 2025-09-15 | Not public |
| PC107 Petkau 1998 Seminars in Neurology Vol 18 3 GB | 2025-09-15 | Not public |
| PC063 Form 10 K Wikipedia Presentation GB | 2025-09-15 | Not public |
| PJ022 Decision de la Chambre de recours 332 de lOEB 2 juin 2003 T 30899 GB | 2025-09-15 | Not public |
| PJ011 TJ Paris 27 juillet 2022 RG n 22 54367 FR | 2025-09-15 | Not public |
| PC089 RNB EP 536 FR | 2025-09-15 | Not public |
| PC068 Decision of the EPO EP 536 GB compressed | 2025-09-15 | Not public |
| PJ087 Regulation n 469 2009 GB | 2025-09-15 | Not public |
| PC140 OLG Munchen Acorda Therapeutics v Ratiopharm 6 October 2022 6 U 3044 22 DE | 2025-09-15 | Not public |
| PJ082 Phosphodiesterase NL Appeal court of the Hague Appel 27082019 NL | 2025-09-15 | Not public |
| PJ030 Decision de la Chambre de recours de lOEB 6 octobre 2004 T 91801 GB | 2025-09-15 | Not public |
| PC078 Info Sheet FAMPYRA 10mg sustained release tablet FR | 2025-09-15 | Not public |
| PC012 Pirmohamed et al BMJ VOLUME 316 25 APRIL 1998 GB | 2025-09-15 | Not public |
| PJ006 CJEU 16 July 2024 Genmab v Hungarian IP Office SPC C 181 24 GB | 2025-09-15 | Not public |
| PC015 Marien et Beaud Guide pratique pour l utilisation de la statistique en recherche 2003 FR | 2025-09-15 | Not public |
| PJ023 Decision de la chambre de recours 332 de l OEB 26 fevrier 2004 T 92600 GB | 2025-09-15 | Not public |
| PC008 BOPI 20 novembre 2015 n 1547 pp 235 237 et 258 FR | 2025-09-15 | Not public |
| PJ025 JUB Division centrale de Munich 16 juillet 2024 Sanofi c Amgen UPCCFI 12023 GB | 2025-09-15 | Not public |
| PC017 Verhagen et al Australian Journal of Physiotherapy 2004 Vol 50 GB | 2025-09-15 | Not public |
| PC087 CCNE Opinion 79 Transposition into French law of the European Directive on clinical trials of medicinal products F | 2025-09-15 | Not public |
| PJ040 Abraxis C 443 17 21 mars 2019 GB | 2025-09-15 | Not public |
| PC045 Declaration of Dr Ron Cohen GB | 2025-09-15 | Not public |
| PC001 Extrait Kbis VIATRIS SANTE FR | 2025-09-15 | Not public |
| PC004 Fampyra SmPC GB | 2025-09-15 | Not public |
| PC076 Kehl Responder Identification in Clinical Trials with Censored Data 2003 GB | 2025-09-15 | Not public |
| PJ075 Guidelines for Examination in the European Patent Office GVII4GB | 2025-09-15 | Not public |
| PC047 US 8 440 703 GB | 2025-09-15 | Not public |
| PC007 Decision et requete de delivrance du CCP n 13 C0033 FR | 2025-09-15 | Not public |
| PC009 Griffin et al The textbook of Pharmaceutical Medicine 1993 Pages 221 222 GB compressed | 2025-09-15 | Not public |
| PC007 Decision et requete de delivrance du CCP n 13 C0033 FR | 2025-09-15 | Not public |
| PC077 Accession of Bulgaria GB | 2025-09-15 | Not public |
| PJ085 DMF NL court of the Hague 1ere instance 22012025 NL | 2025-09-15 | Not public |
| PC025 Bever 1994 The American Neurological Association 1994 volume 23 page 118 S121 GB | 2025-09-15 | Not public |
| PC036 ACTRIMS ECTRIMS Final Program GB compressed | 2025-09-15 | Not public |
| PJ073 EPO BoA 10 July 2025 Eisai v STADA lenvatinib T 193423 GB | 2025-09-15 | Not public |
| PC092 Juillet 1986 Comment determiner la posologie optimale d un medicament FR | 2025-09-15 | Not public |
| PC061 L echelle EDSS Expanded Disability Status Scale FR | 2025-09-15 | Not public |
| PC021 List of documents cited in the oppositions GB | 2025-09-15 | Not public |
| PC134 Patient Leaflet Pymadin BG | 2025-09-15 | Not public |
| PC134 Patient Leaflet Pymadin BG | 2025-09-15 | Not public |
| PC087 CCNE Opinion 79 Transposition into French law of the European Directive on clinical trials of medicinal products F | 2025-09-15 | Not public |
| PC094 Hayes et al 2003 Pharmacokinetic studies of single and multiple oral doses of fampridine Vol 26 n4 pp 185 192 GB | 2025-09-15 | Not public |
| PC088 CHMP 1999 Clinical investigation of medicinal products in the treatment of Parkinson s disease CPMP note for guida | 2025-09-15 | Not public |
| PC072 Germany Teva 20230711 Revocation of patent EP 548 DE | 2025-09-15 | Not public |
| PC002 RCP Fampridine Viatris LP 10mg FR | 2025-09-15 | Not public |
| PJ081 DMF DE OLG Dusseldorf Appel 23022023 DE | 2025-09-15 | Not public |
| PJ013 TJ Paris 18 juin 2025 RG n 23 02356 FR | 2025-09-15 | Not public |
| PC003 Commission Implementing Decision of 27 September 2024 C20246926 GB | 2025-09-15 | Not public |
| PC120 Acorda v Alkem Trial Transcript Volume A GB | 2025-09-15 | Not public |
| PJ019 CA Paris 19 janvier 2021 RG 18 21115 FR | 2025-09-15 | Not public |
| PC070 Germany ratiopharm 20221206 Admissibility of the EP 536 invalidity claim DE | 2025-09-15 | Not public |
| PC083 Barus et al 2022 FR | 2025-09-15 | Not public |
| PC098 Le Progres Article Patients deprived of a medication due to a change of packaging 26 June 2025 FR | 2025-09-15 | Not public |
| PJ077 Bonnes pratiques de distribution ANSM Bulletin officiel n20149bis FR | 2025-09-15 | Not public |
| PC133 SmPC Pymadin BG | 2025-09-15 | Not public |
| PC040 NINDS Fatigue Severity Scale FSS GB | 2025-09-15 | Not public |
| PC044 US 8 007 826 GB | 2025-09-15 | Not public |
| PC014 Journal de la societe statistique de Paris 1956 FR | 2025-09-15 | Not public |
| PC135 Communication between the CEPS and VIATRIS FR | 2025-09-15 | Not public |
| PC091 Dose ranging study Wikipedia GB | 2025-09-15 | Not public |
| PC103 Stefoski et al 1991 4 Aminopyridine in multiple sclerosis Prolonged administration Neurology 1991 GB | 2025-09-15 | Not public |
| PC002 RCP Fampridine Viatris LP 10mg FR | 2025-09-15 | Not public |
| PJ065 CJEU 28 July 2011 Synthon c Mertz memantine C19509 GB | 2025-09-15 | Not public |
| PC041 National Multiple Sclerosis Society Timed 25 Foot Walk T25 FW GB | 2025-09-15 | Not public |
| PJ052 TGI Paris 6 juin 2019 RG n1606916 FR | 2025-09-15 | Not public |
| PC145 Letter from VIATRIS to MERZ of 10 July 2025 FR | 2025-09-15 | Not public |
| PC023 Davis et al 1990 The American Neurological Association 1990 pages 186 192 GB | 2025-09-15 | Not public |
| PC079 Notice on the prices of Fampridine pharmaceutical specialities FR | 2025-09-15 | Not public |
| PC026 Schwid et al 1997 The American Academy of Neurology volume 48 pages 817 821 GB | 2025-09-15 | Not public |
| PC015 Marien et Beaud Guide pratique pour l utilisation de la statistique en recherche 2003 FR | 2025-09-15 | Not public |
| PJ061 Neurim Mylan High Court of Justice 3 juin 2020 EWHC 1362 GB | 2025-09-15 | Not public |
| PC111 Schulz et al 2003 The efficacy of quetiapine vs haloperidol and placebo a meta analytic study of efficacy Schizopp | 2025-09-15 | Not public |
| PC095 CPMP Points to consider multiplicity issues clinical trials 2002 GB | 2025-09-15 | Not public |
| PC008 BOPI 20 novembre 2015 n 1547 pp 235 237 et 258 FR | 2025-09-15 | Not public |
| PC064 USA 20181010 Court of appeal 10 septembre 2018 Acorda v Roxane et al 2017 2078 et 2017 2134 GB | 2025-09-15 | Not public |
| PC148 The fixing of the price and reimboursement rate sante gouv FR | 2025-09-15 | Not public |
| PJ046 Decision de la Chambre de recours de lOEB 20 septembre 2011 T197909 GB | 2025-09-15 | Not public |
| PC006 Demande de CCP sur la base du brevet EP 2 377 536 FR | 2025-09-15 | Not public |
| PC106 Leber et Davis 1998 Threats to the validity of clinical trials employing enrichment strategies for sample selectio | 2025-09-15 | Not public |
| PJ020-Decision de la Chambre de recours 332 de lOEB 13 juillet 2004 T 393 01 GB | 2025-09-15 | Not public |
| PC035 List of references IDS GB | 2025-09-15 | Not public |
| PC109 Lewis 2002 Statistics in Medicine Vol 21 pages 2931 2938 GB | 2025-09-15 | Not public |
| PC071 Germany ratiopharm 20240304 Revocation of patent EP 536 DE | 2025-09-15 | Not public |
| PC033 Acorda Therapeutics Form S1 2003 GB | 2025-09-15 | Not public |
| PC030 Goodman Abstract Poster GB | 2025-09-15 | Not public |
| PJ004 Regulation No 1768 92 GB | 2025-09-15 | Not public |
| PC112 Uryniak et al 2011 Responder Analyses A PhRMA Position Paper Statistics in Biopharmaceutical Research Vol 3 N3 GB | 2025-09-15 | Not public |
| PC110 Temple 1994 Commun Stat Theory Meth Vol 23 pages 449 521 GB | 2025-09-15 | Not public |
| PC084 AFSEP press release of 28 May 2025 FR | 2025-09-15 | Not public |
| PJ069 Dusseldorf Local Division Valeo v Magna 31102024 UPC CFI 3682024 GB | 2025-09-15 | Not public |
| PJ071 Dusseldorf Local Division 30 April 2024 UPCCFI4632023 GB | 2025-09-15 | Not public |
| PC145 Letter from VIATRIS to MERZ of 10 July 2025 FR | 2025-09-15 | Not public |
| PC029 Shargel 1999 Applied Biopharmaceutics and Pharmacokinetics Chapter 7 Extraits pages 169 178 179 GB compressed | 2025-09-15 | Not public |
| PJ026 TGI Paris 7 mai 2010 Hexal c Boehringer RG 0812537 FR | 2025-09-15 | Not public |
| PJ045 Decision de la Chambre de recours de lOEB 1er avril 2009 T 140906 GB | 2025-09-15 | Not public |
| PC069 Board of Appeal of the European Patent Office 4 September 2019 T 0799 16 GB | 2025-09-15 | Not public |
| PJ017 CA Paris 14 novembre 2017 RG n 1502576 FR | 2025-09-15 | Not public |
| PJ005 Accord cadre LEEM CEPS 5 mars 2021 FR | 2025-09-15 | Not public |
| PC034 List of documents requested US 11 102 559 GB | 2025-09-15 | Not public |
| PJ027 Jurisprudences francaises essais de routine FR | 2025-09-15 | Not public |
| PC090 RNB CCP 033 FR | 2025-09-15 | Not public |
| PJ016 TJ Paris 28 mars 2024 RG 2208612 FR | 2025-09-15 | Not public |
| PJ021 Decision de la Chambre de recours 352 de lOEB 22 octobre 1993 T 25392 GB | 2025-09-15 | Not public |
| PC010 ICH Topic E 8 General Considerations for Clinical Trials 17 july 1997 GB | 2025-09-15 | Not public |
| PC097 Screenshots of patients testimonies online 1 2 FR | 2025-09-15 | Not public |
| PJ041 CA Paris 14 fevrier 2020 RG 1903820 Sandoz c MSD FR | 2025-09-15 | Not public |
| PC059 Ellen R Girden Anova repeated measures 1992 GB | 2025-09-15 | Not public |
| PJ079 CA Paris 9 juillet 2025 n2407962 FR | 2025-09-15 | Not public |
| PC016 Piece composite Synthese Wikipiedia sur l ecart type et la valeur P FR | 2025-09-15 | Not public |
| PC099 Matusik 2022 Therapy Nutrients 2022 14 4249 GB | 2025-09-15 | Not public |
| PC131 Disaster Protection Plan Burgas Region Republic of Bulgaria 2012 BG | 2025-09-15 | Not public |
| PC018 EP536 Oral Proceedings GB | 2025-09-15 | Not public |
| PJ059 Decision de la Chambre de recours de lOEB 4 octobre 2016 T250612 GB | 2025-09-15 | Not public |
| PJ003 TJ Paris Ordonnance Viatris c Novartis 04 aout 2022 fingolimod RG n 2254655 FR | 2025-09-15 | Not public |
| PC135 Communication between the CEPS and VIATRIS FR | 2025-09-15 | Not public |
| PC130 4 aminopiridin Spinal Cord Injury Forum RU compressed | 2025-09-15 | Not public |
| PC042 Medical Research Council MRC Scale for Muscle Strength GB | 2025-09-15 | Not public |
| PC121 Acorda v Alkem Trial Transcript Volume B GB | 2025-09-15 | Not public |
| PC131 Disaster Protection Plan Burgas Region Republic of Bulgaria 2012 BG | 2025-09-15 | Not public |
| PC149 IQVIA Data unredacted version GB | 2025-09-15 | Not public |
| PC038 Goodman Poster Placebo Controlled Double blinded Dose Ranging Study of Fampridine SR in Multiple Sclerosis GB | 2025-09-15 | Not public |
| PC049 CA 2 562 277 GB | 2025-09-15 | Not public |
| PC146 Letter from Viatris to Mez dated 2 July 2025 GB | 2025-09-15 | Not public |
| PC104 4 Aminopyridine induces functional improvement in multiple sclerosis patients a neurophysiological study GB | 2025-09-15 | Not public |
| PC070 Germany ratiopharm 20221206 Admissibility of the EP 536 invalidity claim DE | 2025-09-15 | Not public |
| PC151 Declaration Dawid Sierzant du 15 septembre 2025 et annexes GB | 2025-09-15 | Not public |
| PC037 Supplemental Information Disclosure Statement GB | 2025-09-15 | Not public |
| PC027 EP 0 484 186 B1 GB | 2025-09-15 | Not public |
| PJ038 TJ Paris 20 janvier 2022 RG n 1901997 FR | 2025-09-15 | Not public |
| PJ001-Decision du Conseil constitutionnel n 2002 463 DC du 12 decembre 2002 FR | 2025-09-15 | Not public |
| PC082 Extrait de la Base de Donnees Publique des Medicaments Fampridine Viatris 10 mg FR | 2025-09-15 | Not public |
| PC108 Weiner 1998 Can J Neurol Sci Vol 25 pages 93101 GB | 2025-09-15 | Not public |
| PJ051 TGI Rennes 2 septembre 2002 RG n9803029 FR | 2025-09-15 | Not public |
| PJ084 DMF BE Cour dAppel de Bruxelles Appel 30012023 NL | 2025-09-15 | Not public |
| PJ018 TJ Paris 20 juillet 2023 RG n 21 10327 FR | 2025-09-15 | Not public |
| PJ005 Accord cadre LEEM CEPS 5 mars 2021 FR | 2025-09-15 | Not public |
| PJ044 Decision de la Chambre de recours de lOEB du 28 janvier 2019 T 023715 GB | 2025-09-15 | Not public |
| PJ010 Guidelines for examination of the EPO GIV1 GB | 2025-09-15 | Not public |
| PC006 Demande de CCP sur la base du brevet EP 2 377 536 FR | 2025-09-15 | Not public |
| PJ050 Decision de la Chambre de recours 3306 de lOEB 30 mai 2000 T 16596 FR | 2025-09-15 | Not public |
| PJ028 Case law of the Boards of Appeal of the EPO ID71 Reasonable expectation of success GB | 2025-09-15 | Not public |
| PJ081 DMF DE OLG Dusseldorf Appel 23022023 DE | 2025-09-15 | Not public |
| PJ077 Bonnes pratiques de distribution ANSM Bulletin officiel n20149bis FR | 2025-09-15 | Not public |
| PC085 Nuremberg Code GB | 2025-09-15 | Not public |
| PC053 Excerpt from the FDA website Drug Evaluation Process GB | 2025-09-15 | Not public |
| PC141 Sartori et al 1994 GB | 2025-09-15 | Not public |
| PC096 Kehl Responder Identification in Clinical Trials juin 2002 GB | 2025-09-15 | Not public |
| PJ002 CA Paris 14 fevrier 2020 RG 1906114 FR | 2025-09-15 | Not public |
| PJ037 TJ Paris 6 septembre 2024 RG n2106416 FR | 2025-09-15 | Not public |
| PJ047 TJ Paris 22 juin 2023 RG n2002792 FR | 2025-09-15 | Not public |
| PJ031 Decision de la Chambre de recours de lOEB 5 octobre 2000 T 33397 GB | 2025-09-15 | Not public |
| PC022 Sherratt et al 1980 Nature volume 283 5745 pages 570 572 GB | 2025-09-15 | Not public |
| PC097 Screenshots of patients testimonies online 2 2 FR | 2025-09-15 | Not public |
| PJ053 Cour de Cassation 20 novembre 2012 Pourvoi n 1118440 FR | 2025-09-15 | Not public |
| PC132 Free State Gazette edition 33 of 2IV 2002 Unofficial section RU | 2025-09-15 | Not public |
| PJ014 UPC Court of Appeal 13 August 2025 UPCCoA4462025 GB | 2025-09-15 | Not public |
| PJ029 Decision de la Chambre de Recours de lOEB 14 fevrier 1989 T 24988 GB | 2025-09-15 | Not public |
| PC060 O Brien Journal of Hypertension 2003 GB | 2025-09-15 | Not public |
| PJ042 GSK C21013 14 nov 2013 GB | 2025-09-15 | Not public |
| PJ039 Case law of the Boards of Appeal of the EPO I D 74 Try and see solution GB | 2025-09-15 | Not public |
| PC116 SAS Library 1997 Repeated measures ANOVA using SAS PROC GLM GB | 2025-09-15 | Not public |
| PC132 Free State Gazette edition 33 of 2IV 2002 Unofficial section RU | 2025-09-15 | Not public |
| PJ033 Decision de la Chambre de recours de lOEB 25 juillet 2017 T 025915 GB | 2025-09-15 | Not public |
| PJ009 CA Paris 25 mai 2022 RG 21 18398 FR | 2025-09-15 | Not public |
| PC100 EP1732548B9 GB | 2025-09-15 | Not public |
| PC054 Norleans 2001 Statistical Methods for Clinical Trials GB compressed | 2025-09-15 | Not public |
| PC073 USA 20170331 Delaware District Court 31 mars 2017 Acorda v Roxane 14 882 LPS GB | 2025-09-15 | Not public |
| PC136 Russian State Archive of Scientific and Technical Documentation RU | 2025-09-15 | Not public |
| PJ063 Cass Com 10 fevrier 2015 n1320150 FR | 2025-09-15 | Not public |
| PC117 Alhainen et al 1991 Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco EEG in patients | 2025-09-15 | Not public |
| PC092 Juillet 1986 Comment determiner la posologie optimale d un medicament FR | 2025-09-15 | Not public |
| PJ070 Dusseldorf Local Division 9 April 2024 UPCCFI4522023 DE | 2025-09-15 | Not public |
| PJ064 CJEU 28 July 2011 Generics UK c Synaptech galantamine C42709 GB | 2025-09-15 | Not public |
| PC118 Overall 1994 Journal of Clinical Psychology Vol 50 pages 95 102 GB | 2025-09-15 | Not public |
| PC039 Wikipedia page EDSS GB | 2025-09-15 | Not public |
| PC152 Submissions in high resolution GB | 2025-09-15 | Not public |
| PC097 Screenshots of patients testimonies online 2 2 FR | 2025-09-15 | Not public |
| PC143 Chapter 33 Pymadin Paskov et al 1986 GB | 2025-09-15 | Not public |
| PC080 website of the Foundation for Research into Multiple Sclerosis FR | 2025-09-15 | Not public |
| PJ056 Santen C 673 18 GB | 2025-09-15 | Not public |
| PC043 Goodman Diaporama Placebo Controlled Double blinded Dose Ranging Study of Fampridine SR in Multiple Sclerosis GB | 2025-09-15 | Not public |
| PC150 4-Aminopyridine C5H6N2 CID 1727 PubChem GB | 2025-09-15 | Not public |
| PC102 Clinical studies in 20 questions Atelier Presse Clinical trials LEEM 19 May 2011 FR | 2025-09-15 | Not public |
| PC149 IQVIA Data unredacted version GB | 2025-09-15 | Not public |
| PC032 Form S 1 Presentation GB | 2025-09-15 | Not public |
| PJ060 Decision de la Chambre de recours de lOEB 13 septembre 2017 T023916 GB | 2025-09-15 | Not public |
| PC093 Hayes et al 2003 Pharmacokinetics of an Immediate Release Oral Formulation of Fampridine 4 Aminopyridine in Normal | 2025-09-15 | Not public |
| PJ074 Decision de la Chambre de recours de lOEB du 4 octobre 2004 T 111003 GB | 2025-09-15 | Not public |
| PJ080 Munich Local Division 21 May 2024 UPCCFI432023 DE | 2025-09-15 | Not public |
| PJ083 Fingolimod DE OLG Dusseldorf Appel 03082023 DE | 2025-09-15 | Not public |
| PC119 Hamilton et al 1998 Olanzapine versus placebo and haloperidol quality of life and efficacy results on the North Am | 2025-09-15 | Not public |
| PJ057 TJ Paris 12 mai 2021 RG 2153136 Cabazitaxel Sanofi c Teva FR | 2025-09-15 | Not public |
| PC057 FDA Chapter I Food and Drug Administration Department of Health and Human Services Subchapter D Drugs for Human Us | 2025-09-15 | Not public |
| PC114 Cook et al 1983 Design and analysis methods for longitudinal research Ann Rev Public health GB | 2025-09-15 | Not public |
| PC072 Germany Teva 20230711 Revocation of patent EP 548 DE | 2025-09-15 | Not public |
| PJ007 TJ Paris Ordonnance de refere 6 octobre 2022 RG 22 55799 Biogen c Viatris DMF FR | 2025-09-15 | Not public |
| PC137 They are looking for a superpill for Alzheimers Technologies News Standard 2013 BG | 2025-09-15 | Not public |
| PC019 European Medicines Agency Guidelines ICH Topic E4 November 1994 GB | 2025-09-15 | Not public |
| Summon-Oral-Hearing | 2025-09-11 | Not public |
| Order 18-08-2025 summon the oral hearing | 2025-09-11 | Public |
| Hearing-Dates | 2025-08-18 | Not public |
| procedural order timetable and summon OH | 2025-08-18 | Public |
| Panel-Appointment | 2025-08-14 | Not public |
| Acknowledgement of access to case | 2025-08-07 | Not public |
| Notification Of Service | 2025-08-06 | Not public |
| digital tracking La Poste - Service receipt | 2025-08-06 | Not public |
| Panel-Appointment | 2025-08-05 | Not public |
| Letter-for-Service | 2025-08-01 | Not public |
| Notice-to-Accompany-Service-of-Order-for-Measures | 2025-08-01 | Not public |
| Panel-Appointment | 2025-08-01 | Not public |
| Application-For-Measures-Receipt | 2025-08-01 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2025-08-01 | Not public |
| Application-For-Measures-Acknowledgement | 2025-08-01 | Not public |
| Exhibit No. 118 - French Reimbursement Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 505 - CFIEC T-114.06 R 20.07.2006 | 2025-08-01 | Not public |
| Exhibit No. 208 - French SPC Register | 2025-08-01 | Not public |
| Exhibit No. 503 - Toumi et al. External Reference Pricing Simulation | 2025-08-01 | Not public |
| Exhibit No. 125 - Notice Letter 18.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 210 - French SPC Grant Decision | 2025-08-01 | Not public |
| Exhibit No. 012 - Viatris France webpage | 2025-08-01 | Not public |
| Exhibit No. 701 - Application - French Translation | 2025-08-01 | Not public |
| Exhibit No. 011 - Viatris Generics webpage | 2025-08-01 | Not public |
| Application for provisional measures | 2025-08-01 | Not public |
| Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 002 - Merz Businesses webpage | 2025-08-01 | Not public |
| Exhibit No. 100 - Merz FAMPYRA Launch News | 2025-08-01 | Not public |
| Exhibit No. 128 - Reply Letter 10.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 119 - French Public Institution Approval Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 601 - CoA Mammut v Orthovox 25.09.2024 | 2025-08-01 | Not public |
| Exhibit No. 204 - Merz GmbH and Merz France Short Form Sub-Licence | 2025-08-01 | Not public |
| Exhibit No. 507 - Article L. 138-9 | 2025-08-01 | Not public |
| Exhibit No. 008 - FR Commercial Register - Merz Pharma France | 2025-08-01 | Not public |
| Exhibit No. 124 - Monthly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 200 - French Patent Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 112 - FAMPYRA EU Definitive Approval | 2025-08-01 | Not public |
| Exhibit No. 210 - French SPC Grant Decision | 2025-08-01 | Not public |
| Exhibit No. 118 - French Reimbursement Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 700 - Proof of payment | 2025-08-01 | Not public |
| Exhibit No. 301 - Federal Patent Court Decision | 2025-08-01 | Not public |
| Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024 | 2025-08-01 | Not public |
| Exhibit No. 104 - Lublin - Reingold 1996 | 2025-08-01 | Not public |
| Application for provisional measures | 2025-08-01 | Not public |
| Exhibit No. 508 - Ceilings for Discounts Decree | 2025-08-01 | Not public |
| Exhibit No. 115 - FAMPRIDINE VIATRIS PIL | 2025-08-01 | Not public |
| Exhibit No. 103 - Lucchinetti et al. 2000 | 2025-08-01 | Not public |
| Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006 | 2025-08-01 | Not public |
| Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 109 - FAMPYRA EPAR Summary | 2025-08-01 | Not public |
| Exhibit No. 009 - FR Commercial Register - Viatris Sante | 2025-08-01 | Not public |
| Exhibit No. 117 - French Generics List Decision 19.09.2024 | 2025-08-01 | Not public |
| Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022 | 2025-08-01 | Not public |
| Exhibit No. 200 - French Patent Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 606 - LD Munich 10x Genomics v NanoString 19.09.2023 | 2025-08-01 | Not public |
| Exhibit No. 405 - EMA Guideline MR dosage forms | 2025-08-01 | Not public |
| Exhibit No. 012 - Viatris France webpage | 2025-08-01 | Not public |
| Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH | 2025-08-01 | Not public |
| Exhibit No. 105 - Kasser et al. 2017 | 2025-08-01 | Not public |
| Exhibit No. 209 - French SPC Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 004 - Acorda Bankruptcy Proceedings and Liquidation Plan | 2025-08-01 | Not public |
| Exhibit No. 509 - Substituting Generic Product on Ameli | 2025-08-01 | Not public |
| Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022 | 2025-08-01 | Not public |
| Exhibit No. 501 - 2021 Health Products Agreement | 2025-08-01 | Not public |
| Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC | 2025-08-01 | Not public |
| Exhibit No. 608 - CoA 10x Genomics v NanoString 11.03.2024 | 2025-08-01 | Not public |
| Exhibit No. 302 - EPO T 0421.14 Decision | 2025-08-01 | Not public |
| Exhibit No. 504 - LEEM 2021 Economic Extracts | 2025-08-01 | Not public |
| Exhibit No. 209 - French SPC Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 122 - French Fampridine MA | 2025-08-01 | Not public |
| Exhibit No. 107 - FAMPYRA French Directory | 2025-08-01 | Not public |
| Exhibit No. 206 - French Patent Register | 2025-08-01 | Not public |
| Exhibit No. 120 - French Price Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 013 - Acorda webpage | 2025-08-01 | Not public |
| Exhibit No. 205 - EP 536 Patent | 2025-08-01 | Not public |
| Exhibit No. 126 - Reply Letter 2.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 003 - Merz Therapeutics website | 2025-08-01 | Not public |
| Exhibit No. 504 - LEEM 2021 Economic Extracts | 2025-08-01 | Not public |
| Exhibit No. 128 - Reply Letter 10.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 113 - EMA Assessment Report | 2025-08-01 | Not public |
| Exhibit No. 117 - French Generics List Decision 19.09.2024 | 2025-08-01 | Not public |
| Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory | 2025-08-01 | Not public |
| Exhibit No. 212 - Acorda and Merz LLC Short Form Assignment | 2025-08-01 | Not public |
| Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 206 - French Patent Register | 2025-08-01 | Not public |
| Exhibit No. 509 - Substituting Generic Product on Ameli | 2025-08-01 | Not public |
| Exhibit No. 124 - Monthly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 607 - CoA 10x Genomics v NanoString 26.02.2024 | 2025-08-01 | Not public |
| Exhibit No. 009 - FR Commercial Register - Viatris Sante | 2025-08-01 | Not public |
| Exhibit No. 502 - Kanavos et al. External Reference Pricing Implementation | 2025-08-01 | Not public |
| Exhibit No. 120 - French Price Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 203 - Merz LLC and Merz GmbH Short Form Licence | 2025-08-01 | Not public |
| Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory | 2025-08-01 | Not public |
| Exhibit No. 123 - Weekly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 106 - Larocca 2011 | 2025-08-01 | Not public |
| Exhibit No. 119 - French Public Institution Approval Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 506 - CFIEC T-201.04 R 22.12.2004 | 2025-08-01 | Not public |
| Exhibit No. 400 - WHO INN List 35 | 2025-08-01 | Not public |
| Exhibit No. 121 - French Co-Payment Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 110 - FAMPYRA EU Conditional Approval | 2025-08-01 | Not public |
| Exhibit No. 202 - Official Intellectual Property Bulletin 25.13 | 2025-08-01 | Not public |
| Exhibit No. 122 - French Fampridine MA | 2025-08-01 | Not public |
| Exhibit No. 127 - Notice Letter 4.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 605 - CoA Sumi Agro v Syngenta 3.03.2025 | 2025-08-01 | Not public |
| Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 512 - Performance-Based Remuneration | 2025-08-01 | Not public |
| Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 213 - French Patent Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 508 - Ceilings for Discounts Decree | 2025-08-01 | Not public |
| Exhibit No. 111 - EU Marketing Decisions | 2025-08-01 | Not public |
| Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 115 - FAMPRIDINE VIATRIS PIL | 2025-08-01 | Not public |
| Exhibit No. 010 - Viatris Products webpage | 2025-08-01 | Not public |
| Exhibit No. 404 - Acorda SEC S-1 Form | 2025-08-01 | Not public |
| Exhibit No. 402 - Goodman Slideshow | 2025-08-01 | Not public |
| Exhibit No. 301 - Federal Patent Court Decision | 2025-08-01 | Not public |
| Exhibit No. 211 - French SPC Grant Publication | 2025-08-01 | Not public |
| Exhibit No. 005 - US Commercial Register - Merz Pharmaceuticals LLC | 2025-08-01 | Not public |
| Exhibit No. 108 - FAMPYRA SmPC | 2025-08-01 | Not public |
| Exhibit No. 401 - Goodman Poster | 2025-08-01 | Not public |
| Exhibit No. 107 - FAMPYRA French Directory | 2025-08-01 | Not public |
| Exhibit No. 121 - French Co-Payment Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 202 - Official Intellectual Property Bulletin 25.13 | 2025-08-01 | Not public |
| Exhibit No. 300 - EPO T 0799.16 Decision | 2025-08-01 | Not public |
| Exhibit No. 208 - French SPC Register | 2025-08-01 | Not public |
| Exhibit No. 207 - UPC Opt-Out Extract | 2025-08-01 | Not public |
| Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 123 - Weekly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 211 - French SPC Grant Publication | 2025-08-01 | Not public |
| Exhibit No. 403 - Goodman Abstract | 2025-08-01 | Not public |
| Exhibit No. 507 - Article L. 138-9 | 2025-08-01 | Not public |
| Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006 | 2025-08-01 | Not public |
| Exhibit No. 001 - Merz History webpage | 2025-08-01 | Not public |
| Exhibit No. 201 - French SPC Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC | 2025-08-01 | Not public |
| Exhibit No. 213 - French Patent Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 600 - LD Dusseldorf Valeo v Magna 31.10.2024 | 2025-08-01 | Not public |
| Exhibit No. 512 - Performance-Based Remuneration | 2025-08-01 | Not public |
| Exhibit No. 604 - CoA Biolitec v Light Guide 24.02.2025 | 2025-08-01 | Not public |
| Exhibit No. 006 - Merz - Acorda Asset News | 2025-08-01 | Not public |
| Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024 | 2025-08-01 | Not public |
| Exhibit No. 008 - FR Commercial Register - Merz Pharma France | 2025-08-01 | Not public |
| Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH | 2025-08-01 | Not public |
| Exhibit No. 501 - 2021 Health Products Agreement | 2025-08-01 | Not public |
| Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 201 - French SPC Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC | 2025-08-01 | Not public |
| Exhibit No. 213 - French Patent Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 202 - Official Intellectual Property Bulletin 25.13 | 2025-08-01 | Not public |
| Exhibit No. 127 - Notice Letter 4.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 013 - Acorda webpage | 2025-08-01 | Not public |
| Exhibit No. 604 - CoA Biolitec v Light Guide 24.02.2025 | 2025-08-01 | Not public |
| Exhibit No. 701 - Application - French Translation | 2025-08-01 | Not public |
| Exhibit No. 012 - Viatris France webpage | 2025-08-01 | Not public |
| Exhibit No. 123 - Weekly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 104 - Lublin - Reingold 1996 | 2025-08-01 | Not public |
| Exhibit No. 507 - Article L. 138-9 | 2025-08-01 | Not public |
| Exhibit No. 607 - CoA 10x Genomics v NanoString 26.02.2024 | 2025-08-01 | Not public |
| Exhibit No. 502 - Kanavos et al. External Reference Pricing Implementation | 2025-08-01 | Not public |
| Exhibit No. 107 - FAMPYRA French Directory | 2025-08-01 | Not public |
| Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006 | 2025-08-01 | Not public |
| Exhibit No. 301 - Federal Patent Court Decision | 2025-08-01 | Not public |
| Exhibit No. 128 - Reply Letter 10.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 401 - Goodman Poster | 2025-08-01 | Not public |
| Exhibit No. 126 - Reply Letter 2.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 404 - Acorda SEC S-1 Form | 2025-08-01 | Not public |
| Exhibit No. 501 - 2021 Health Products Agreement | 2025-08-01 | Not public |
| Exhibit No. 122 - French Fampridine MA | 2025-08-01 | Not public |
| Exhibit No. 503 - Toumi et al. External Reference Pricing Simulation | 2025-08-01 | Not public |
| Exhibit No. 512 - Performance-Based Remuneration | 2025-08-01 | Not public |
| Exhibit No. 128 - Reply Letter 10.07.2025 | 2025-08-01 | Not public |
| Exhibit No. 208 - French SPC Register | 2025-08-01 | Not public |
| Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022 | 2025-08-01 | Not public |
| Exhibit No. 700 - Proof of payment | 2025-08-01 | Not public |
| Exhibit No. 211 - French SPC Grant Publication | 2025-08-01 | Not public |
| Exhibit No. 106 - Larocca 2011 | 2025-08-01 | Not public |
| Exhibit No. 003 - Merz Therapeutics website | 2025-08-01 | Not public |
| Exhibit No. 117 - French Generics List Decision 19.09.2024 | 2025-08-01 | Not public |
| Exhibit No. 105 - Kasser et al. 2017 | 2025-08-01 | Not public |
| Exhibit No. 122 - French Fampridine MA | 2025-08-01 | Not public |
| Exhibit No. 004 - Acorda Bankruptcy Proceedings and Liquidation Plan | 2025-08-01 | Not public |
| Exhibit No. 507 - Article L. 138-9 | 2025-08-01 | Not public |
| Exhibit No. 110 - FAMPYRA EU Conditional Approval | 2025-08-01 | Not public |
| Exhibit No. 012 - Viatris France webpage | 2025-08-01 | Not public |
| Exhibit No. 300 - EPO T 0799.16 Decision | 2025-08-01 | Not public |
| Exhibit No. 211 - French SPC Grant Publication | 2025-08-01 | Not public |
| Exhibit No. 512 - Performance-Based Remuneration | 2025-08-01 | Not public |
| Exhibit No. 405 - EMA Guideline MR dosage forms | 2025-08-01 | Not public |
| Exhibit No. 103 - Lucchinetti et al. 2000 | 2025-08-01 | Not public |
| Exhibit No. 118 - French Reimbursement Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 207 - UPC Opt-Out Extract | 2025-08-01 | Not public |
| Exhibit No. 118 - French Reimbursement Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 117 - French Generics List Decision 19.09.2024 | 2025-08-01 | Not public |
| Exhibit No. 121 - French Co-Payment Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 508 - Ceilings for Discounts Decree | 2025-08-01 | Not public |
| Exhibit No. 204 - Merz GmbH and Merz France Short Form Sub-Licence | 2025-08-01 | Not public |
| Exhibit No. 205 - EP 536 Patent | 2025-08-01 | Not public |
| Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH | 2025-08-01 | Not public |
| Exhibit No. 119 - French Public Institution Approval Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 124 - Monthly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 200 - French Patent Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 108 - FAMPYRA SmPC | 2025-08-01 | Not public |
| Exhibit No. 206 - French Patent Register | 2025-08-01 | Not public |
| Exhibit No. 504 - LEEM 2021 Economic Extracts | 2025-08-01 | Not public |
| Exhibit No. 302 - EPO T 0421.14 Decision | 2025-08-01 | Not public |
| Exhibit No. 006 - Merz - Acorda Asset News | 2025-08-01 | Not public |
| Exhibit No. 403 - Goodman Abstract | 2025-08-01 | Not public |
| Exhibit No. 120 - French Price Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 605 - CoA Sumi Agro v Syngenta 3.03.2025 | 2025-08-01 | Not public |
| Exhibit No. 111 - EU Marketing Decisions | 2025-08-01 | Not public |
| Exhibit No. 009 - FR Commercial Register - Viatris Sante | 2025-08-01 | Not public |
| Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH | 2025-08-01 | Not public |
| Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024 | 2025-08-01 | Not public |
| Exhibit No. 010 - Viatris Products webpage | 2025-08-01 | Not public |
| Exhibit No. 124 - Monthly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 119 - French Public Institution Approval Order 19.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 402 - Goodman Slideshow | 2025-08-01 | Not public |
| Exhibit No. 509 - Substituting Generic Product on Ameli | 2025-08-01 | Not public |
| Exhibit No. 115 - FAMPRIDINE VIATRIS PIL | 2025-08-01 | Not public |
| Exhibit No. 115 - FAMPRIDINE VIATRIS PIL | 2025-08-01 | Not public |
| Exhibit No. 509 - Substituting Generic Product on Ameli | 2025-08-01 | Not public |
| Exhibit No. 506 - CFIEC T-201.04 R 22.12.2004 | 2025-08-01 | Not public |
| Exhibit No. 209 - French SPC Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 212 - Acorda and Merz LLC Short Form Assignment | 2025-08-01 | Not public |
| Exhibit No. 201 - French SPC Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 121 - French Co-Payment Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 202 - Official Intellectual Property Bulletin 25.13 | 2025-08-01 | Not public |
| Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 505 - CFIEC T-114.06 R 20.07.2006 | 2025-08-01 | Not public |
| Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 210 - French SPC Grant Decision | 2025-08-01 | Not public |
| Exhibit No. 203 - Merz LLC and Merz GmbH Short Form Licence | 2025-08-01 | Not public |
| Exhibit No. 601 - CoA Mammut v Orthovox 25.09.2024 | 2025-08-01 | Not public |
| Exhibit No. 100 - Merz FAMPYRA Launch News | 2025-08-01 | Not public |
| Exhibit No. 608 - CoA 10x Genomics v NanoString 11.03.2024 | 2025-08-01 | Not public |
| Exhibit No. 113 - EMA Assessment Report | 2025-08-01 | Not public |
| Exhibit No. 504 - LEEM 2021 Economic Extracts | 2025-08-01 | Not public |
| Application for provisional measures | 2025-08-01 | Not public |
| Exhibit No. 109 - FAMPYRA EPAR Summary | 2025-08-01 | Not public |
| Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory | 2025-08-01 | Not public |
| Exhibit No. 011 - Viatris Generics webpage | 2025-08-01 | Not public |
| Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory | 2025-08-01 | Not public |
| Exhibit No. 606 - LD Munich 10x Genomics v NanoString 19.09.2023 | 2025-08-01 | Not public |
| Exhibit No. 501 - 2021 Health Products Agreement | 2025-08-01 | Not public |
| Exhibit No. 120 - French Price Notice 22.11.2024 | 2025-08-01 | Not public |
| Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 208 - French SPC Register | 2025-08-01 | Not public |
| Exhibit No. 209 - French SPC Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 508 - Ceilings for Discounts Decree | 2025-08-01 | Not public |
| Exhibit No. 210 - French SPC Grant Decision | 2025-08-01 | Not public |
| Exhibit No. 001 - Merz History webpage | 2025-08-01 | Not public |
| Exhibit No. 301 - Federal Patent Court Decision | 2025-08-01 | Not public |
| Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 123 - Weekly GERS Fampridine Sales | 2025-08-01 | Not public |
| Exhibit No. 206 - French Patent Register | 2025-08-01 | Not public |
| Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC | 2025-08-01 | Not public |
| Exhibit No. 002 - Merz Businesses webpage | 2025-08-01 | Not public |
| Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022 | 2025-08-01 | Not public |
| Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 200 - French Patent Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006 | 2025-08-01 | Not public |
| Exhibit No. 600 - LD Dusseldorf Valeo v Magna 31.10.2024 | 2025-08-01 | Not public |
| Exhibit No. 009 - FR Commercial Register - Viatris Sante | 2025-08-01 | Not public |
| Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024 | 2025-08-01 | Not public |
| Exhibit No. 201 - French SPC Registration Entries | 2025-08-01 | Not public |
| Exhibit No. 213 - French Patent Annuity Extract | 2025-08-01 | Not public |
| Exhibit No. 008 - FR Commercial Register - Merz Pharma France | 2025-08-01 | Not public |
| Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 107 - FAMPYRA French Directory | 2025-08-01 | Not public |
| Exhibit No. 400 - WHO INN List 35 | 2025-08-01 | Not public |
| Exhibit No. 008 - FR Commercial Register - Merz Pharma France | 2025-08-01 | Not public |
| Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 112 - FAMPYRA EU Definitive Approval | 2025-08-01 | Not public |
| Exhibit No. 005 - US Commercial Register - Merz Pharmaceuticals LLC | 2025-08-01 | Not public |
| Exhibit No. 125 - Notice Letter 18.06.2025 | 2025-08-01 | Not public |
| Exhibit No. 401 - Goodman Poster | 2025-07-31 | Not public |
| Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH | 2025-07-31 | Not public |
| Exhibit No. 507 - Article L. 138-9 | 2025-07-31 | Not public |
| Exhibit No. 011 - Viatris Generics webpage | 2025-07-31 | Not public |
| Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 210 - French SPC Grant Decision | 2025-07-31 | Not public |
| Exhibit No. 201 - French SPC Registration Entries | 2025-07-31 | Not public |
| Exhibit No. 605 - CoA Sumi Agro v Syngenta 3.03.2025 | 2025-07-31 | Not public |
| Exhibit No. 104 - Lublin - Reingold 1996 | 2025-07-31 | Not public |
| Exhibit No. 501 - 2021 Health Products Agreement | 2025-07-31 | Not public |
| Exhibit No. 106 - Larocca 2011 | 2025-07-31 | Not public |
| Exhibit No. 213 - French Patent Annuity Extract | 2025-07-31 | Not public |
| Exhibit No. 126 - Reply Letter 2.07.2025 | 2025-07-31 | Not public |
| Exhibit No. 209 - French SPC Annuity Extract | 2025-07-31 | Not public |
| Exhibit No. 501 - 2021 Health Products Agreement | 2025-07-31 | Not public |
| Exhibit No. 204 - Merz GmbH and Merz France Short Form Sub-Licence | 2025-07-31 | Not public |
| Exhibit No. 001 - Merz History webpage | 2025-07-31 | Not public |
| Exhibit No. 302 - EPO T 0421.14 Decision | 2025-07-31 | Not public |
| Exhibit No. 402 - Goodman Slideshow | 2025-07-31 | Not public |
| Exhibit No. 125 - Notice Letter 18.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC | 2025-07-31 | Not public |
| Exhibit No. 006 - Merz - Acorda Asset News | 2025-07-31 | Not public |
| Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022 | 2025-07-31 | Not public |
| Exhibit No. 201 - French SPC Registration Entries | 2025-07-31 | Not public |
| Exhibit No. 123 - Weekly GERS Fampridine Sales | 2025-07-31 | Not public |
| Exhibit No. 503 - Toumi et al. External Reference Pricing Simulation | 2025-07-31 | Not public |
| Exhibit No. 108 - FAMPYRA SmPC | 2025-07-31 | Not public |
| Exhibit No. 203 - Merz LLC and Merz GmbH Short Form Licence | 2025-07-31 | Not public |
| Exhibit No. 131 - FAMPYRA French Price Notice 04.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 202 - Official Intellectual Property Bulletin 25.13 | 2025-07-31 | Not public |
| Exhibit No. 128 - Reply Letter 10.07.2025 | 2025-07-31 | Not public |
| Exhibit No. 600 - LD Dusseldorf Valeo v Magna 31.10.2024 | 2025-07-31 | Not public |
| Exhibit No. 504 - LEEM 2021 Economic Extracts | 2025-07-31 | Not public |
| Exhibit No. 109 - FAMPYRA EPAR Summary | 2025-07-31 | Not public |
| Exhibit No. 012 - Viatris France webpage | 2025-07-31 | Not public |
| Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 206 - French Patent Register | 2025-07-31 | Not public |
| Exhibit No. 509 - Substituting Generic Product on Ameli | 2025-07-31 | Not public |
| Exhibit No. 118 - French Reimbursement Order 19.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 607 - CoA 10x Genomics v NanoString 26.02.2024 | 2025-07-31 | Not public |
| Exhibit No. 512 - Performance-Based Remuneration | 2025-07-31 | Not public |
| Exhibit No. 008 - FR Commercial Register - Merz Pharma France | 2025-07-31 | Not public |
| Exhibit No. 124 - Monthly GERS Fampridine Sales | 2025-07-31 | Not public |
| Exhibit No. 103 - Lucchinetti et al. 2000 | 2025-07-31 | Not public |
| Exhibit No. 512 - Performance-Based Remuneration | 2025-07-31 | Not public |
| Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006 | 2025-07-31 | Not public |
| Exhibit No. 117 - French Generics List Decision 19.09.2024 | 2025-07-31 | Not public |
| Exhibit No. 508 - Ceilings for Discounts Decree | 2025-07-31 | Not public |
| Exhibit No. 120 - French Price Notice 22.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 012 - Viatris France webpage | 2025-07-31 | Not public |
| Exhibit No. 112 - FAMPYRA EU Definitive Approval | 2025-07-31 | Not public |
| Exhibit No. 129 - FAMPYRA French Reimbursement Order 02.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 003 - Merz Therapeutics website | 2025-07-31 | Not public |
| Exhibit No. 209 - French SPC Annuity Extract | 2025-07-31 | Not public |
| Exhibit No. 504 - LEEM 2021 Economic Extracts | 2025-07-31 | Not public |
| Exhibit No. 510 - Order Pharmacists-Health Insurance- 31.03.2022 | 2025-07-31 | Not public |
| Exhibit No. 008 - FR Commercial Register - Merz Pharma France | 2025-07-31 | Not public |
| Exhibit No. 505 - CFIEC T-114.06 R 20.07.2006 | 2025-07-31 | Not public |
| Application for provisional measures | 2025-07-31 | Not public |
| Exhibit No. 606 - LD Munich 10x Genomics v NanoString 19.09.2023 | 2025-07-31 | Not public |
| Exhibit No. 200 - French Patent Registration Entries | 2025-07-31 | Not public |
| Exhibit No. 004 - Acorda Bankruptcy Proceedings and Liquidation Plan | 2025-07-31 | Not public |
| Exhibit No. 119 - French Public Institution Approval Order 19.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 212 - Acorda and Merz LLC Short Form Assignment | 2025-07-31 | Not public |
| Exhibit No. 502 - Kanavos et al. External Reference Pricing Implementation | 2025-07-31 | Not public |
| Exhibit No. 301 - Federal Patent Court Decision | 2025-07-31 | Not public |
| Exhibit No. 122 - French Fampridine MA | 2025-07-31 | Not public |
| Exhibit No. 604 - CoA Biolitec v Light Guide 24.02.2025 | 2025-07-31 | Not public |
| Exhibit No. 119 - French Public Institution Approval Order 19.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 208 - French SPC Register | 2025-07-31 | Not public |
| Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 005 - US Commercial Register - Merz Pharmaceuticals LLC | 2025-07-31 | Not public |
| Exhibit No. 122 - French Fampridine MA | 2025-07-31 | Not public |
| Exhibit No. 007 - DE Commercial Register - Merz Therapeutics GmbH | 2025-07-31 | Not public |
| Exhibit No. 115 - FAMPRIDINE VIATRIS PIL | 2025-07-31 | Not public |
| Exhibit No. 107 - FAMPYRA French Directory | 2025-07-31 | Not public |
| Exhibit No. 124 - Monthly GERS Fampridine Sales | 2025-07-31 | Not public |
| Exhibit No. 009 - FR Commercial Register - Viatris Sante | 2025-07-31 | Not public |
| Exhibit No. 509 - Substituting Generic Product on Ameli | 2025-07-31 | Not public |
| Exhibit No. 127 - Notice Letter 4.07.2025 | 2025-07-31 | Not public |
| Exhibit No. 128 - Reply Letter 10.07.2025 | 2025-07-31 | Not public |
| Exhibit No. 114 - FAMPRIDINE VIATRIS SmPC | 2025-07-31 | Not public |
| Exhibit No. 110 - FAMPYRA EU Conditional Approval | 2025-07-31 | Not public |
| Exhibit No. 123 - Weekly GERS Fampridine Sales | 2025-07-31 | Not public |
| Exhibit No. 400 - WHO INN List 35 | 2025-07-31 | Not public |
| Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 300 - EPO T 0799.16 Decision | 2025-07-31 | Not public |
| Exhibit No. 202 - Official Intellectual Property Bulletin 25.13 | 2025-07-31 | Not public |
| Exhibit No. 500 - Notice Amendment Generic Distribution- 6.01.2006 | 2025-07-31 | Not public |
| Exhibit No. 700 - Proof of payment | 2025-07-31 | Not public |
| Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory | 2025-07-31 | Not public |
| Exhibit No. 211 - French SPC Grant Publication | 2025-07-31 | Not public |
| Exhibit No. 608 - CoA 10x Genomics v NanoString 11.03.2024 | 2025-07-31 | Not public |
| Exhibit No. 117 - French Generics List Decision 19.09.2024 | 2025-07-31 | Not public |
| Exhibit No. 211 - French SPC Grant Publication | 2025-07-31 | Not public |
| Exhibit No. 210 - French SPC Grant Decision | 2025-07-31 | Not public |
| Exhibit No. 121 - French Co-Payment Notice 22.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 009 - FR Commercial Register - Viatris Sante | 2025-07-31 | Not public |
| Exhibit No. 200 - French Patent Registration Entries | 2025-07-31 | Not public |
| Exhibit No. 010 - Viatris Products webpage | 2025-07-31 | Not public |
| Exhibit No. 118 - French Reimbursement Order 19.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 404 - Acorda SEC S-1 Form | 2025-07-31 | Not public |
| Exhibit No. 116 - FAMPRIDINE VIATRIS French Directory | 2025-07-31 | Not public |
| Exhibit No. 208 - French SPC Register | 2025-07-31 | Not public |
| Exhibit No. 205 - EP 536 Patent | 2025-07-31 | Not public |
| Exhibit No. 405 - EMA Guideline MR dosage forms | 2025-07-31 | Not public |
| Exhibit No. 507 - Article L. 138-9 | 2025-07-31 | Not public |
| Exhibit No. 601 - CoA Mammut v Orthovox 25.09.2024 | 2025-07-31 | Not public |
| Exhibit No. 213 - French Patent Annuity Extract | 2025-07-31 | Not public |
| Exhibit No. 113 - EMA Assessment Report | 2025-07-31 | Not public |
| Exhibit No. 121 - French Co-Payment Notice 22.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024 | 2025-07-31 | Not public |
| Exhibit No. 403 - Goodman Abstract | 2025-07-31 | Not public |
| Exhibit No. 207 - UPC Opt-Out Extract | 2025-07-31 | Not public |
| Exhibit No. 132 - FAMPYRA French Co-Payment Notice 04.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 105 - Kasser et al. 2017 | 2025-07-31 | Not public |
| Exhibit No. 206 - French Patent Register | 2025-07-31 | Not public |
| Exhibit No. 120 - French Price Notice 22.11.2024 | 2025-07-31 | Not public |
| Exhibit No. 301 - Federal Patent Court Decision | 2025-07-31 | Not public |
| Exhibit No. 511 - Amendment Order Pharmacists-Health Insurance-5.07.2024 | 2025-07-31 | Not public |
| Exhibit No. 100 - Merz FAMPYRA Launch News | 2025-07-31 | Not public |
| Exhibit No. 506 - CFIEC T-201.04 R 22.12.2004 | 2025-07-31 | Not public |
| Exhibit No. 013 - Acorda webpage | 2025-07-31 | Not public |
| Exhibit No. 111 - EU Marketing Decisions | 2025-07-31 | Not public |
| Exhibit No. 002 - Merz Businesses webpage | 2025-07-31 | Not public |
| Exhibit No. 130 - FAMPYRA French Public Institution Approval Order 02.06.2025 | 2025-07-31 | Not public |
| Exhibit No. 508 - Ceilings for Discounts Decree | 2025-07-31 | Not public |
| Exhibit No. 107 - FAMPYRA French Directory | 2025-07-31 | Not public |
| Exhibit No. 115 - FAMPRIDINE VIATRIS PIL | 2025-07-31 | Not public |